PureTech bags $200M from sale of Karuna shares — still siz­zling from promis­ing schiz­o­phre­nia da­ta

Cash­ing in on the ex­u­ber­ance around Karuna Ther­a­peu­tics and its po­ten­tial block­buster CNS drug, PureTech has sold a chunk of the biotech’s shares to Gold­man Sachs for $200 mil­lion.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER